Mitsuo Terada, MD, PhD@乳腺科医· @MamMa_mimumemo · X·· 2 天前评分70
正文
中国からのHER2-ADC trastuzumab-rezetecanのHER2-lowへの1st line/2nd lineでのPhase3 HORIZON-Breast06試験。
有意にPFSを延長。OSも延長傾向。すごいな...
#ESMO26
1555 浏览 · 19 赞 · 3 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：Mitsuo Terada, MD, PhD@乳腺科医 · x.com